The Pharma Data
AUGUST 3, 2021
Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. The trial compared tirzepatide to insulin glargine in adults with type 2 diabetes and increased cardiovascular risk. Business Development/Other Developments.
Drug Discovery World
SEPTEMBER 6, 2022
Fully booked service providers for manufacturing and sample analyses and more immune-oriented use of gene and cell therapies.” – CBO Aino Kalervo, and VP of Business Development? .” – Andrew Scharenberg, Umoja Biopharma CEO. . Víctor Cervera-Carrascón, Tilt Bio. .
XTalks
AUGUST 2, 2023
They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Merck’s total global revenue from Lagevrio was $5.68 billion in 2022. billion ($8.72 billion USD) in 2022.
Expert insights. Personalized for you.
52 
Let's personalize your content